Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study

Arthritis Care & Research
Arthur KavanaughStephen Xu

Abstract

To evaluate long-term outcomes in psoriatic arthritis (PsA) patients who achieved or did not achieve minimal disease activity (MDA) through 5 years of golimumab treatment in the GO-REVEAL trial. The GO-REVEAL trial was a phase III, randomized, double-blind trial with placebo-control through week 24 followed by an open-label extension of golimumab 50/100 mg treatment up to 5 years. In these post-hoc analyses, MDA was defined by the presence of ≥5 of 7 PsA outcome measures (≤1 swollen joint, ≤1 tender joint, Psoriasis Area and Severity Index [PASI] ≤1, patient pain score ≤15, patient global disease activity score ≤20 [range 0-100], Health Assessment Questionnaire disability index [HAQ DI] ≤0.5, and ≤1 tender enthesis point). Treatment with golimumab yielded significantly higher MDA response rates versus patients randomized to placebo at week 14 (23.5% versus 1.0%; P < 0.0001), week 24 (28.1% versus 7.7%; P < 0.0001), and week 52 (42.4% versus 30.2%; P = 0.037). MDA was achieved at least once by ∼50% of golimumab-treated patients overall. Irrespective of treatment randomization, achievement of MDA at ≥3 and ≥4 consecutive visits was associated with significantly less radiographic progression and more improvement in MDA components ...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Jan 17, 2009·Annals of the Rheumatic Diseases·L C CoatesP S Helliwell
Jul 1, 2010·Arthritis Care & Research·Laura C Coates, Philip S Helliwell
Jul 9, 2014·Nature Reviews. Rheumatology·Ignazio OlivieriAngela Padula

❮ Previous
Next ❯

Citations

Jan 26, 2016·Expert Review of Clinical Immunology·V Chandran, A B Maharaj
Jun 28, 2011·Annales de dermatologie et de vénéréologie·H BachelezS Boulinguez
May 13, 2018·Nature Reviews. Rheumatology·Joy FeldDafna Gladman
Aug 26, 2017·Immunotherapy·Maria UrdanetaSonya Abraham
Jul 17, 2016·The Journal of Rheumatology·Barry J SheaneVinod Chandran
Nov 17, 2017·The Journal of Rheumatology·Laure GossecFrank Behrens
Jan 8, 2019·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Christian K HuhnStephanie Finzel
Feb 20, 2020·RMD Open·Emma DuresLaura C Coates
Jan 18, 2018·Expert Review of Clinical Immunology·Fabio Massimo PerrottaEnnio Lubrano
Oct 12, 2017·Arthritis Research & Therapy·Leonieke J J van MensDominique L P Baeten
Aug 22, 2017·Journal of Psoriasis and Psoriatic Arthritis·Ladan AfifiWilson Liao
Apr 5, 2018·Drugs·Musaab Elmamoun, Vinod Chandran
Dec 23, 2019·Current Rheumatology Reports·Robert Chao, Arthur Kavanaugh
Oct 17, 2017·Current Opinion in Rheumatology·Enrique R SorianoMaria L Acosta-Felquer
Nov 25, 2018·Rheumatology and Therapy·Laura J TuckerPhilip S Helliwell
Oct 6, 2020·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Tsen-Fang TsaiUNKNOWN Taiwan Rheumatology Association (TRA) and the Taiwanese Association for Psoriasis and Skin Immunology (TAPSI)
Nov 17, 2020·Frontiers in Medicine·Angelo FassioLuca Idolazzi
Jun 7, 2019·Best Practice & Research. Clinical Rheumatology·Anna Molto, Joachim Sieper
Apr 3, 2021·The Journal of Rheumatology·Eva Galíndez-AgirregoikoaUNKNOWN Tofacitinib PsA Clinical Practice Collaborative Group

❮ Previous
Next ❯

Methods Mentioned

BETA
MDA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.